Letrozole boosts live birth rate in patients with PCOS undergoing FET

  • Zhang J & al.
  • Fertil Steril
  • 21 May 2019

  • International Clinical Digest
Access to the full content of this site is available only to registered healthcare professionals. Access to the full content of this site is available only to registered healthcare professionals.

Takeaway

  • Letrozole (Femara) stimulation is associated with a higher live birth rate (LBR) compared with artificial cycle in patients with PCOS undergoing frozen-thawed embryo transfer (FET).

Why this matters

  • The best approach for endometrial preparation before FET is unclear and has been poorly studied in patients with PCOS.

Key results

  • Letrozole-stimulated cycle FET was associated with a higher ongoing pregnancy rate (aOR, 1.24; 95% CI, 1.02-1.51) and LBR (aOR, 1.33; 95% CI, 1.09-1.61) compared with artificial-cycle FET in adjusted analysis.
  • Letrozole-stimulated cycle FET was associated with a lower rate of miscarriage (aOR, 0.51; 95% CI, 0.35-0.74) compared with artificial-cycle FET in adjusted analysis.
  • Endometrial thickness was greater in the letrozole group compared with the artificial-cycle group (11.91 vs 10.10 mm; P<.001 on the day of progesterone supplementation vs mm embryo transfer>

Study design

  • 2664 patients with PCOS, 1571 who received letrozole-stimulated cycle FET and 1093 who received artificial-cycle FET, were analyzed for outcomes.
  • Funding: National Key Research and Development Program of China, National Natural Science Foundation of China, China Postdoctoral Science Foundation.

Limitations

  • Retrospective study.
  • Endometrial receptivity assay not performed on both groups of patients.